Bloomberg Anywhere Remote Login Bloomberg Terminal Request a Demo

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $1.20 USD
Change Today -0.02 / -1.64%
Volume 34.4K
ALXA On Other Exchanges
Symbol
Exchange
NASDAQ CM
As of 10:50 AM 09/4/15 All times are local (Market data is delayed by at least 15 minutes).

alexza pharmaceuticals inc (ALXA) Snapshot

Open
$1.25
Previous Close
$1.22
Day High
$1.25
Day Low
$1.12
52 Week High
09/4/14 - $3.35
52 Week Low
07/9/15 - $0.80
Market Cap
23.3M
Average Volume 10 Days
22.4K
EPS TTM
$-2.24
Shares Outstanding
19.4M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for ALEXZA PHARMACEUTICALS INC (ALXA)

alexza pharmaceuticals inc (ALXA) Related Businessweek News

No Related Businessweek News Found

alexza pharmaceuticals inc (ALXA) Details

Alexza Pharmaceuticals, Inc., a pharmaceutical company, focuses on the research, development, and commercialization of proprietary products for the acute treatment of central nervous system conditions worldwide. The company’s product candidates are based on a proprietary technology, the Staccato system, which vaporizes an excipient-free drug to form a condensation aerosol that, when inhaled, allows for rapid systemic drug delivery. It offers ADASUVE (Staccato loxapine) inhalation powder for the acute treatment of agitation associated with schizophrenia or bipolar I disorder in adults. The company also engages in developing AZ-002 (Staccato alprazolam) for treating patients with acute repetitive seizures, as well as in Phase 2a study for patients with epilepsy; and AZ-007 (Staccato zaleplon) for the treatment of insomnia in patients who have difficulty falling asleep, including patients who awake in the middle of the night and have difficulty falling back asleep. It has collaboration agreement with Grupo Ferrer Internacional S.A. The company was formerly known as Alexza Molecular Delivery Corporation and changed its name to Alexza Pharmaceuticals, Inc. in July 2005.Alexza Pharmaceuticals, Inc. was incorporated in 2000 and is based in Mountain View, California.

81 Employees
Last Reported Date: 03/13/15
Founded in 2000

alexza pharmaceuticals inc (ALXA) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $535.6K
Chief Financial Officer, Principal Accounting...
Total Annual Compensation: $315.0K
Executive Vice President of Research & Develo...
Total Annual Compensation: $290.0K
Compensation as of Fiscal Year 2014.

alexza pharmaceuticals inc (ALXA) Key Developments

Alexza Pharmaceuticals Inc. Reports Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended June 30, 2015

Alexza Pharmaceuticals Inc. reported unaudited consolidated earnings results for the second quarter and six months ended June 30, 2015. For the quarter, the company reported total revenue of $1,875,000 against $1,484,000 a year ago. Loss from operations was $9,441,000 against $11,349,000 a year ago. Net loss was $12,450,000 or $0.63 per share basic and diluted against $5,962,000 or $0.34 per share basic and diluted a year ago. For the six months, the company reported total revenue of $2,580,000 against $3,650,000 a year ago. Loss from operations was $22,444,000 against $20,152,000 a year ago. Net loss was $12,854,000 or $0.65 per share basic and diluted against $16,697,000 or $0.96 per share basic and diluted a year ago.

Alexza Pharmaceuticals Inc. to Report Q2, 2015 Results on Aug 06, 2015

Alexza Pharmaceuticals Inc. announced that they will report Q2, 2015 results at 5:00 PM, US Eastern Standard Time on Aug 06, 2015

Alexza Pharmaceuticals Inc., Q2 2015 Earnings Call, Aug 06, 2015

Alexza Pharmaceuticals Inc., Q2 2015 Earnings Call, Aug 06, 2015

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ALXA:US $1.20 USD -0.02

ALXA Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Alkermes PLC $64.40 USD +1.49
Aradigm Corp $7.04 USD 0.00
Dr Reddy's Laboratories Ltd 4,053 INR -156.35
Durect Corp $2.09 USD +0.07
Endo International PLC $73.58 USD -0.88
View Industry Companies
 

Industry Analysis

ALXA

Industry Average

Valuation ALXA Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 5.1x
Price/Book NM Not Meaningful
Price/Cash Flow NM Not Meaningful
TEV/Sales NM Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ALEXZA PHARMACEUTICALS INC, please visit www.alexza.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.